Asset
ARIPIPRAZOLE LAUROXIL
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01626456 | phase3 | completed | 2012-06-01 | 2015-04-01 | Alkermes, Inc. | A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) |
| NCT01493726 | phase1 | completed | 2011-12-01 | 2013-06-01 | Alkermes, Inc. | A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia |
| NCT02634320 | phase4 | completed | 2015-12-01 | 2017-07-11 | Alkermes, Inc. | A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia |
| NCT02636842 | phase1 | completed | 2015-12-01 | 2016-06-01 | Alkermes, Inc. | A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder |
| NCT03345979 | phase3 | completed | 2017-11-15 | 2019-03-12 | Alkermes, Inc. | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia |
FDA applications (0)
This company has no applications containing this asset.